Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Generalized myasthenia gravis
Economic burden and healthcare resource utilization
10 evidence topics · 11 sources
Incremental annual costs of newly diagnosed gMG compared with matched controls: U.S. claims, 2017 to 2023
“Adults with newly diagnosed gMG were identified from Komodo Research data (January 1, 2017, to September 30, 2023).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The gMG cohort (mean follow-up = 32.7 months) compared with the non-MG cohort (mean follow-up = 31.3 months) had 2.4, 1.6, and 1.9 times more inpatient days, emergency department visits, and outpatient visits annually, respectively (all P < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean annual all-cause total health care costs in the gMG cohort were $43,872 higher than in the non-MG cohort ($58,341 vs $14,469; P < 0.001); 59.3% of the difference was driven by pharmacy costs (mostly immunoglobulin).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Prediagnosis weakness and fatigue symptoms, exacerbation or crisis, and use of immunoglobulin were important factors significantly associated with high health care costs in the gMG cohort (all P < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Costs associated with exacerbations and crises in newly diagnosed gMG: U.S. claims
“Among 6,195 patients with gMG (mean age: 61.1 years; female: 49.1%), higher event risk was associated with use of immunoglobulin [hazard ratio (HR) = 1.54], baseline dysarthria (HR = 1.45), general and other muscle-specific weaknesses (HR = 1.38), use of non-steroidal immunosuppressants (HR = 1.37), dysphagia (HR = 1.28), weight loss (HR=1.27), dyspnea (HR = 1.23), ptosis (HR = 1.20), absence of other autoimmune disorders (HR=1.18), and male sex (HR = 1.15; all p < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After re-weighting, patients with a clinical event had higher number of inpatient admissions [rate ratio (RR) = 6.02], emergency visits (RR = 1.91), and outpatient visits (RR = 1.58; all p < 0.05) in the 12 months post-index. Mean total healthcare costs were $70,792 higher among patients with a clinical event ($95,821 vs. $25,029, p < 0.001), driven by immunoglobulin and inpatient costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Incremental costs and event-related costs in prevalent and incident gMG: U.S. claims, 2017 to 2023
“Analyses included 16,561 gMG patients (12,813 prevalent and 3748 incident) and 105,716 non-gMG controls. Among prevalent and incident gMG patients, respectively, MG exacerbation occurred during follow-up in 12.2 and 22.0% and myasthenic crisis in 6.0 and 12.4%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“After weighting, gMG patients (median follow-up 696 days) experienced more frequent all-cause HCRU encounters and >4-fold higher healthcare costs ($5420 PPPM or ∼$65,000 per annum) versus non-gMG controls ($1298 PPPM or ∼$15,500 per annum).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among MG patients, those with MG exacerbation/myasthenic crisis, respectively, experienced means of 3.02/3.35 hospitalizations, 1.91/2.13 emergency department encounters, 12.70/13.39 skilled nursing facility encounters, and 67.86/75.52 outpatient encounters during follow-up; associated costs were $17,113/$18,640 PPPM (or ∼$205,000/$224,000 per annum).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Incremental monthly costs and the effect of comorbidities and acute events: U.S. claims, 2017 to 2021
“The gMG and matched non-MG cohorts each contained 2,739 patients. Mean incremental healthcare costs associated with MG were $4,155 (gMG: $5,567; non-MG: $1,411), with differences driven by incremental inpatient costs of $2,166 (gMG: $2,617; non-MG: $452); all p < 0.001.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients with gMG in cardiometabolic (n = 1,859), psychiatric (n = 1,308), and exacerbation/crisis (n = 419) subgroups, mean monthly healthcare costs were $6,660, $7,443, and $17,330, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
First-year costs after diagnosis by payer: U.S. commercial and Medicare claims, 2016 to 2021
“The final analytic cohort included 3,700 patients with MG and 37,000 controls. On average, patients were aged 54 years, with 60% being female. The difference-in-difference estimates of the total health care cost for MG diagnosis in commercial and Medicare patients were $25,799 and $4,927, respectively (P < 0.01).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Costs in newly diagnosed and previously diagnosed patients and around crisis events: U.S. claims, 2014 to 2019
“Mean HCRU and costs were higher for newly diagnosed patients compared with previously diagnosed patients (hospitalizations: 0.46 vs. 0.34; all-cause costs: $26,419.20 vs. $24,941.47; direct costs for gMG treatments: $9,890.37 vs. $9,186.47) and further increased for patients with exacerbation events (hospitalizations: 0.72; all-cause costs: $43,734.15; direct costs for gMG treatments: $21,550.02).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For patients who experienced crisis events, HCRU and costs markedly increased during the 12 months immediately before the crisis event (hospitalizations: 1.35; all-cause costs: $49,236.68) compared with the 2 preceding years and increased further during the 12 months following the crisis index date (hospitalizations: 2.78; all-cause costs: $173,956.99).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Costs in patients treated with chronic IVIg or multiple nonsteroidal immunosuppressants
“Compared with the reference cohort (n = 2992), the MG crisis rate was approximately twice as high in both the chronic IVIg (n = 324) and multiple NSIST (n = 291) cohorts (p < 0.001); and the MG exacerbation rate was approximately four-fold higher in the chronic IVIg cohort (p < 0.001) and three-fold higher in the multiple NSIST cohort (p < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median annual MG-related inflation-adjusted total healthcare costs were higher in the chronic IVIg ($81,900) and multiple NSIST ($30,300) cohorts than in the reference cohort ($2540).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Costs by glucocorticoid exposure: U.S. commercial claims
“Among 8833 patients with gMG, 5076 (57.5%) had no GC use and 3757 (42.5%) had any GC use (≥5 mg/d: 1537 [40.9%]; ≥10 mg/d: 860 [22.9%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Incident GC toxicities were higher in patients with any GC use than those without (61.9% vs 52.3%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Annual all-cause costs were >2x higher among patients with any GC use than those with no GC use ($76,381 vs $35,309). GC acute and chronic toxicities and costs tended to increase with increasing GC use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hospitalization trends: U.S. Nationwide Inpatient Sample and Medicare, 2010 to 2019
“Hospitalization rates for 19,715 unique adult patients and 56,822 admissions increased from 2010 to 2019 at an average annualized rate of 4.9% (MG noncrisis: 4.4%; MG crisis: 6.8%; all p < 0.001). Readmission rates were approximately 20% in each study year for both crisis and noncrisis hospitalizations; the in-hospital mortality rate averaged 1.8%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The average LOS was stable over the study period, ranging from 11.3 to 13.1 days, but was consistently longer for MG crisis admissions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Range of direct and indirect costs across studies: systematic reviews
“Across studies, the mean per-patient annual direct medical cost of illness was estimated at between $760 and $28,780, and cost per hospitalization between $2550 and $164,730. The indirect cost of illness was estimated at $80 and $3550.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Costs varied considerably by patient characteristics, and drivers of the direct medical cost of illness included intravenous immunoglobulin and plasma exchange, myasthenic crisis, mechanical ventilatory support, and hospitalizations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“1374 records were identified initially, and 44 were included in the final review.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Direct costs include treatment and follow-up in the primary and specialist health care. They were estimated to €3 500–12 000 per MG patient per year in the Nordic countries, similar in other European countries, and higher in United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Intangible costs include value of lost life-years and reduced quality of life, which are rarely assessed, but have been estimated to be half of the total societal MG costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote